225 related articles for article (PubMed ID: 31814435)
1. De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course.
Ramachandran P; Sahni S; Wang JC
J Investig Med High Impact Case Rep; 2019; 7():2324709619893546. PubMed ID: 31814435
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review.
Zhang Y; Wang X; Liu Y; Sun C; Shi W; Huang H
Cancer Biol Ther; 2018 Jul; 19(7):549-553. PubMed ID: 29611764
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
[TBL] [Abstract][Full Text] [Related]
5. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
6. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
[TBL] [Abstract][Full Text] [Related]
7. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract][Full Text] [Related]
8. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases].
Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J
Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in de novo CD5+ diffuse large B cell lymphoma.
Jain P; Fayad LE; Rosenwald A; Young KH; O'Brien S
Am J Hematol; 2013 Sep; 88(9):798-802. PubMed ID: 23695956
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
11. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
12. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
15. Childhood de novo CD5+ Diffuse Large B-cell Lymphoma: a Separate Entity?
Coffey A; Allen A; Thomsen MB; Sulis ML; Murty V; Hoehn D
Ann Clin Lab Sci; 2015; 45(5):574-81. PubMed ID: 26586711
[TBL] [Abstract][Full Text] [Related]
16. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome.
Yamaguchi M; Ohno T; Oka K; Taniguchi M; Ito M; Kita K; Shiku H
Br J Haematol; 1999 Jun; 105(4):1133-9. PubMed ID: 10554834
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
Shimono J; Miyoshi H; Kiyasu J; Sato K; Kamimura T; Eto T; Miyagishima T; Nagafuji K; Teshima T; Ohshima K
Br J Haematol; 2017 Sep; 178(5):719-727. PubMed ID: 28493517
[TBL] [Abstract][Full Text] [Related]
18. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
19. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F
J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]